The Administrative Core will provide management services to each of the Projects and Cores in thisProgram. The Core will provide financial, adminstrative, and clerical services for the PI, the Co-Pi, ProjectLeaders, and Core Leaders for all grant-related activities. These activites include the preparation of thiscompeting renewal, non-competing renewals including progress reports, preparation of budgets,communication with the NIH regarding renewals and all financial interactions, and assurance that the labssupported by this Program are in full compliance with all institutional, state and federal regulations. Core Awill also coordinate and scheduling all meetings related to the function of the Program, including monthlymeetings of all Project and Core Leaders, and members of their respective laboratories, as well as twiceyearly meetings of the Internal and External Advisory Boards. Core A will also coordinate efforts with off-siteinvestiators at the three neighboring institutions, Brigham and Women's Hospital, Beth Israel-DeaconessHospital, and Children's Hospital of Boston, as well as interaction with the investigators at the DFCI. Dr.Gilliland is the PI and Director of this Core, and will serve as the overall scientific director and chiefadministrator. Dr. Griffin is the Co-Pi and will assist in these operations, particaulrly with regard to matterswith the on-site investigators and clinical programs at the DFCI. He will assist Dr. Gilliland in monitoringprotocol performance and will assist in protocol development. Alberto Jamarillo is a highly skilledadministrator with experience in management of fiscal and administrative matters for large program projectgrants. He will serve as Administrative Facilitator, and coordinate Program administration and fiscaloversight with Dr. Gilliland and Dr. Griffin. Alberto Jamarillo will be assisted by Betsy Kelley, a GrantsManagement Specialist/Post Award, and Mariha Duarte, an administrative assistant, in coordination with Dr.Gilliland and Dr. Griffin, to manage budgets between participating institutions, prepare reports including noncompetingrenewals, interface with the financial officers of each participating institution in the Program, andserve as an interface between these groups and the NIH. In addition, the Administrative Core will assurecompliance with appropriate regulations regarding experimentation with human subjects, (including genderand minority participation) and vertebrate animals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066996-11A1
Application #
7406278
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Project Start
2007-12-01
Project End
2012-11-30
Budget Start
2007-12-01
Budget End
2009-03-31
Support Year
11
Fiscal Year
2008
Total Cost
$43,199
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Bolin, Sara; Borgenvik, Anna; Persson, Camilla U et al. (2018) Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene 37:2850-2862
Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:
Nauffal, Mary; Redd, Robert; Ni, Jian et al. (2018) Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract :1078155218791333
Stein, Eytan M; Garcia-Manero, Guillermo; Rizzieri, David A et al. (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661-2669
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117

Showing the most recent 10 out of 376 publications